Calbiotech Cardiolipin IgM Elisa Kit

Product Description

Measurement of IgG, IgM and IgA cardiolipin autoantibodies (aCL) by EIA is the standard procedure for the detection ofantiphospholipid antibodies (aPL) in patients with suspected antiphospholipid syndrome (APS). High aCL concentrationsare associated with increased risk of venous and arterial thrombosis, recurrent pregnancy loss and thrombocytopenia.Patients with the anti-cardiolipin syndrome have one of the above clinical features and have antibodies to cardiolipinand/or a positive lupus anticoagulant test. The antibodies present to cardiolipin may be of the IgG, IgA, IgM isotypes.Testing for the various antibody isotypes to cardiolipin aid in diagnosis of the anti-phospholipid syndrome in patients withSLE or lupus-like disorders. Binding of aCL to CL in patients with autoimmune diseases is dependent on the presence ofthe cofactor beta-2-glycoprotein I (beta2-GPI); this binding is independent of beta-2-GPI in patients with infectiousdiseases (e.g., syphilis, tuberculosis). Recognition of the role of beta-2- GPI in the binding of aCL led to development ofassay for direct measurement of beta-2-GPI autoantibodies using beta-2-GPI as antigen, allowing a clear distinctionbetween beta-2-GPI autoantibodies and those that bind to CL alone